ArticleJournal of orthopaedic case reports2025
Epidural Steroid Injections for Lumbar Disc Herniation and Lumbar Degenerative Disc Disease.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lower back pain, a leading cause of global disability, is commonly attributed to lumbar disc herniation (LDH) and lumbar degenerative disc disease (LDDD). These conditions result in nerve inflammation and compression, causing significant pain and mobility limitations. Epidural steroid injections (ESIs) are a minimally invasive treatment targeting inflammation to provide pain relief and improve functionality. Objective: This study aimed to evaluate the short-term efficacy of ESIs in patients with LDH and LDDD, analyze Visual Analog Scale (VAS) pain scores over time, and assess factors influencing treatment outcomes. Materials and Methods: A prospective study of 50 patients with lumbar radiculopathy due to LDH or LDDD was conducted between November 2022 and November 2024. Inclusion criteria comprised adults (>18 years) with radicular pain unresponsive to conservative treatments. Demographics, medical history, radiculopathy levels, and VAS scores were recorded at baseline and during follow-ups at 3 and 6 months. Statistical analyses evaluated differences based on diagnosis, gender, body mass index (BMI), and radiculopathy levels. Results: The cohort (mean age 47 years) included 66% males and 34% females. LDH accounted for 76% of cases, and LDDD for 24%. Significant pain reduction was observed post-injection (VAS scores from ~7 to ~4 at 3 months). However, symptoms partially recurred by 6 months (VAS ~5.5). No significant differences in outcomes were noted across gender, BMI, or radiculopathy levels (P > 0.05). Conclusion: ESIs effectively reduce pain in LDH and LDDD patients during short-term follow-ups. However, symptom recurrence indicates the need for sustained management strategies. While ESIs offer temporary relief, their integration into a comprehensive treatment plan is essential for optimizing long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.